References
- McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Pahl E. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2017;135(17), e927–e999. doi:10.1161/cir.0000000000000484
- Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatrica, 83(10), 1057–1060. doi:10.1111/j.1651-2227.1994.tb12985.x
- Morishita KA, Goldman RD. Kawasaki disease recognition and treatment. Can Fam Physician. 2020;66(8): 577–579.
- Pilania RK, Bhattarai D, Singh S. Controversies in diagnosis and management of Kawasaki disease. World Journal of Clinical Pediatrics, 2018;7(1), 27–35. doi:10.5409/wjcp.v7.i1.27
- Marchesi A, Rigante D, Cimaz R, Ravelli A, Tarissi de Jacobis I, Rimini A, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Italian Journal of Pediatrics. 2021;47:16. https://doi.org/10.1186/s13052-021-00962-4
- Vignesh P, Bhattad S, Singhal M, Singh S. A 5-year-old boy with only fever and giant coronary aneurysms: the enigma of Kawasaki disease? Rheumatology International, 2016;36(8), 1191–1193. doi:10.1007/s00296-016-3490-7
- Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Accessed May 22, 2020. https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19
- Whittaker E, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [published online June 8, 2020]. JAMA. https://doi.org/10.1001/jama.2020.10369
- Elias MD, McCrindle BW, Larios G, Choueiter NF, Dahdah N, Harahsheh AS, et al. Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Survey From the International Kawasaki Disease Registry. CJC Open [Internet]. 2020 Nov 1;2(6):632–40.
- Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. Published May 14, 2020.
- WHO. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. 15 May 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
- Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D’Anitga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. Advance online publication, doi: 10.1016/S0140-6736(20)31129-6
- Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–e288. doi: 10.1016/S1473-3099(20)30651-4.
- Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2020 Nov 21:1–14. doi: 10.1007/s00296-020-04749-4
- Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56:29–36.
- Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26. doi: 10.1186/1546-0096-12-26.
- Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016;75(3), 481–489. doi:10.1136/annrheumdis-2015-208982
- Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Annals of the Rheumatic Diseases, 2012;71(12), 2059–2061. doi:10.1136/annrheumdis-2012-201658
- Printz BF, Sleeper LA, Newburger JW, Minich LL, Bradley T, Cohen MS, Frank D, Li JS, Margossian R, Shirali G, Takahashi M, Colan SD; Pediatric Heart Network Investigators. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011;57:86–92. doi: 10.1016/j.jacc.2010.08.619.
- Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med. 1986;315:341–347. doi:10.1056/NEJM198608073150601.
- Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–1639. doi: 10.1056/NEJM199106063242305.
- Kato H. Cardiovascular complications in Kawasaki disease: Coronary artery lumen and long-term consequences. Progress in Pediatric Cardiology. 2004 Dec 1;19(2 SPEC.ISS.):137–45.
- Jindal AK, Pilania RK, Prithvi A, Guleria S, Singh S. Kawasaki disease: characteristics, diagnosis, and unusual presentations. Expert Review of Clinical Immunology. 2019; 3;15(10):1089–104.
- Pilania RK, Jindal AK, Bhattarai D, Naganur SH, Singh S. Cardiovascular Involvement in Kawasaki Disease Is Much More Than Mere Coronary Arteritis. Frontiers in Pediatrics. 2020;24;0:627.